Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515281 · ClinicalTrials.gov registry record · Phase 2
Inhaled Nitric Oxide and Neuroprotection in Premature Infants
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 273
- Enrollment target
NCT00515281 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 273 participants.
The verdict
NCT00515281, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 273 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether inhaled nitric oxide improves the neurological outcome for premature infants.
Interventions
- DRUG inhaled nitric oxide
- DRUG oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2008-05 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515281
The ClinicalTrials.gov registry entry for NCT00515281 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which inhaled nitric oxide is the first listed.
NCT00515281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515281 about?
NCT00515281 is a clinical study titled "Inhaled Nitric Oxide and Neuroprotection in Premature Infants". The purpose of this study is to determine whether inhaled nitric oxide improves the neurological outcome for premature infants.
What is the current status of trial NCT00515281?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 273 participants. The study started on 2008-05. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT00515281?
The interventions under investigation include: inhaled nitric oxide (DRUG), oxygen (DRUG).
Who is sponsoring clinical trial NCT00515281?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.